Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.
Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.
It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.
BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
The company is headquartered in West Vancouver, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 12, 25 | -4.35 Decreased by -1.88 K% | - |
| Oct 15, 25 | -9.24 Decreased by -13.10 K% | -12.11 Increased by +23.70% |
| Jun 12, 25 | -1.64 Decreased by -1.59 K% | -1.76 Increased by +6.82% |
| Mar 17, 25 | -2.33 Decreased by -228.17% | -1.94 Decreased by -20.10% |
| Dec 12, 24 | -0.22 Increased by +56.00% | -0.30 Increased by +26.67% |
| Oct 23, 24 | -0.07 Increased by +53.33% | -0.46 Increased by +84.78% |
| Jun 14, 24 | 0.11 Increased by +114.29% | -0.55 Increased by +120.00% |
| Mar 18, 24 | -0.71 Decreased by -914.29% | -0.20 Decreased by -255.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jan 31, 26 | N/A Decreased by N/A% | -7.22 M Increased by +20.31% | - - |
| Oct 31, 25 | 0.00 Decreased by N/A% | -11.37 M Decreased by -43.76% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 25 | 225.34 K Increased by +893.96% | -11.06 M Decreased by -561.44% | Decreased by -4.91 K% Increased by +33.45% |
| Apr 30, 25 | 0.00 Decreased by N/A% | -8.72 M Decreased by -477.35% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 25 | 0.00 Decreased by N/A% | -9.06 M Increased by +40.65% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 24 | 0.00 Decreased by N/A% | -7.91 M Decreased by -198.03% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 24 | 22.67 K Increased by +N/A% | -1.67 M Increased by +48.26% | Decreased by -7.37 K% Decreased by N/A% |
| Apr 30, 24 | 0.00 Decreased by N/A% | 2.31 M Increased by +134.65% | Increased by +N/A% Decreased by N/A% |